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Plasma Brain Natriuretic Peptlde Concentrations Predict Survival 
After Acute Myocarclial Infarction 
NAOSHI ARAKAWA, MD, MOTOYUKI NAKAMURA, MD, HIDEHIKO AOKI, MD, 
KAT!XlHIKO HIRAMORI, MD 
oqiahbrs. This study sought to examine wbetber plasma brain 
8strl~ pepttde levels can predkt pmtptosis after myocardial 
infhrctlon. 
ll4lc@und* it has been suggerlted that collce0tlatlons of 
plasma lnnla aatr4welk peptlde reBecl left ventrlcnbw fun&n. 
Althou@ the prop&3 after q yocardlai lnthettoa depeads 011 
m&al left ventricular fun&q it Is sot known wbetber plasma 
kveis of brain natrluretk peptide after lb onset of myo- 
cardlal bsfamllon can be usd to predkt loag-term oatcome, 
Metha& Plasma brain aatrturetk peptide and atrlal aatri- 
nrelk peptide levels 0s well OS levaslve hemodynamic variables 
were mensurul in 70 patknts attb acute myocardial iaftuctioa (53 
me& 17 wVmen; mesa age 65 years). MeasuRmeats were obtaiaed 
on admlssioa (mean 6 b after onset) and oo day 2 after oaset. 
Meaa rollowap period was 18 moatbs. 
l&m&s. Plasma bmin natrluretk peptide kvels nwasured 00 
adrissh aad day 2 correlated riga&aatly wtth bemodyaamic 
varlobb whkh art Influenced by left venlrkelar fuoction. How- 
ever, plasma atdai aatriuretk peptide levels correlated w&b aooe 
of the hemodynomk varlabks measufed on admissioa; and of 
Brain natriuretic peptide and atrial natriuretic peptide have 
similar biologic activities. They induce diuresis, natriuresiy vase. 
relaxatioq and inhibition of the rer ‘n-angic~tensin-aldrone 
system in both the healthy (i-4) and dkeased conditions (5-10). 
However. the principal sites where Ihc% natrirtretic peptides are 
synthesized may bc different. that of brain natriurctic peptide 
being in the ventricular cardiomyqte (I i-13) and that of atrial 
natriuretic peptide in the atrium (14-16). Plasma concentrations 
of both brain natriuretic peptide and atrial natriuretic peptide are 
reported to be increased according to the severity of chronic 
congestive heart failure (12,17-20). Plasma brain natriuretic 
peptide concentration may reflect left ventricular function in 
various cardiac diseases (21-24). In aeutc myocardial infarction, 
plasma brain natriurctic peptide I& is Ibought to increase as left 
ventricular cly\function progresses (25,26). Beiqause prognosis 
those measured oa day 2, plasma atrial aatrturetic peptlde levels 
comlated oaly with left atrial filllag pressare. During the 
follow-up pertod (meon I8 + 7 months), 11 patlentil dkd of 
cardiac causes. By Kaplan-Meier analysis, it was huad that 
pathts with plasma brain aatriurotk peptide level6 b@er thaa 
the medlaa kvel, both on admission and on day 2, Bad sigalfh 
caatly bigher mortality rates than those w&h the submedlaa kvel 
(on admlssloa, p -Z 0.01: 00 day 2, p < 0.05). However, only the 
plasma atrlal aatriuretk peptide level obtaiaed immediately after 
admission was slgoUlaotly teluted to survival (p c 0.01). By Cm 
pmporUonal basardr model analysis oPtbe aoainvasive variables, 
it was found that plasma braia oatriuretic peptlde coaceatratloa 
was acre closely releted lo sulvlval after myocardial iafarction 
(p = 0.0001). 
Concludan. lnerensed pkna brain aatriu&ic peptide con- 
rentratfons in the early or subacute phase of myocmdial iahre- 
tioo are a powerfid q minvasive iadkator of poor progaosis, 
possibly retkctiog residual left veotrkular ftmction after myocar- 
dial infarction. 
(J Am Cdl Cdial19%;2?:1656-61) 
after qocardial infarction is known to depend on residual left 
ventricular function (272x), plasma brain natriuretic peptide 
concentration may be useful in predicting a prognosis after 
myocardial infarction. 
Plasma atrial natriuretic peptide level has been used in pre- 
dicting a prognosis after myocar&l infarction (29-32). However. 
the sampling time-points for measuring plasma atrial natriuretic 
peptide varied: within 12 h (29), from 12 to 24 h (31), or 3 days 
(30.32) after onset. We demonstrated previously that plasma 
brain natriuretic peptide level is significantty increased from 12 h 
thmugh 48 h after the onset of mvdia: infarction, whereas 
plasma aIrial natriuretic peptide level did not change significantly 
(33). Thus in the present study, we used two diierent sampling 
timepoints: on admksion and on day 2 after onset. We compared 
the prognostic value of plasma brain natriuretic peptide measure- 
ments with those of atrial nalriuretic pcptidc in patients with 
acute myocardial infarction 
Methods 
S@ecfs. From fanuary 1992 Lo March iW3.7W cxmse~u- 
he patients (53 men. 17 women: mcan age 65 + i2 ye=) 
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Tabte 1. Compsruoa of Ctiaical. Hemodyaak aud Biochemical 
Variables Grouped According to &dhu~ Hasma tzvet of Brata 
Nntrturetic Pcpttt on Admhutoa 
admitted to our hospital coronary care unit within 12 h of onset 
were subjects of the present study. Patients with cardiogenic 
shock or renal failure (serum creatinine ~1.5 mg/dl), or both, 
were excluded from this study. The diagnosis of myocardial 
infarction was based on a history of typical chest paln, typical 
elcctiocardiographic -hengee and an increase in serum cre- 
mine hinase level. Based on electrocardiographic criteria, the 
site of infarction wa: anterior in 32 patients., inferior in 27 
patients and at other locations in 11 patients. Pii-two patients 
were admitted to the hospital within 6 h of onset, and these 
patients received coronary reperhrsion therapy. Corona9 in- 
tervention was chosen, randomly according to the separate 
treatment protocols in our corona9 care unit (infusion of 
tissue plasminogen activator, n = 30; emergency percutaneous 
transhtmittal corona9 angloplasty, n = 22). Eighteen patients 
were admitted from 6 to I2 h after onset and received only 
conventional treatment (that is, nitrate and Bdocaine). The 
study was apptwed by the ethics committee of our hospital, 
and informed consent was obtained from all patients. 
B&d sampBoB and assays. Immediately after admission 
(mean, 6 f 5 h after onset) and on da) 2 after onset, blood was 
withdrawn from a forearm vein for measurement of plasma 
brain natriuretic peptide and atrial natriuretic peptide conren- 
trations. Blood samples were collected into tubes containmg 
10 mg of EDTA-2Na and ZJOO U of aprotinii, centrifuged 
immediately (3,000 rpm at 4”C), and then stored at -8PC 
until they were analyxed. Plasma levels of brain natriuretic 
peptide and atrial natriuretic peptide were determined using a 
ccmmercial radioimmunoamay hit (brain natriuretic peptide, 
Peninsula Laboratories; atrial natriuretic peptide, Amersham) 
after c&action using a SepPah C-18 column (Waters Chro- 
matography Division, Millipore) BS described in our previs*us 
reports (10‘34). These assays were performed in dupliite. The 
minimum detectable level of brain natriuretic peptide was :ts 
than 1.7 pg per tube, and cross-reactivity with human atruu 
natriuretic peptide was less than 0.01%. The intraassay and 
interassay coefficients of variation for brain natriuretic peptide 
assays were 12% and 1946, respectively. In our laboratory, 
mean plasma levels of atrial natrketic peptide and brain 
natriuretic peptide in age-matched healthy subjects with no 
evidence of myocrrdial ischemia were 29 t 15 p&ml (n = 17) 
and I8 L? 6 pg!ml (n = l3), respectively. 
li~i varlablc& Puhnona9 capillary wedge pres- 
sure and cardiac output were measured using a Swan-Ganx 
catheter (Baxter Corp., Edwards Division) immediately atIer 
admissiin and on day 2 after onset in all patients. Left 
ventricular ejection fraction and left ventricular enddiastolic 
pressure were determined during ventricular catheterixation in 
patient* treated with reperfttsion therapy at the time of 
admission. The clinii characteristics of the patients groqed 
according to the median plasma tevel of brain natriuretic 
peptide on admisstmn are summarked in Table I. Corona9 
reperf&on for acute phase of myocardiat infarction was 
succe&ul in all patients who had received the therapy. 
!&Ubtki analysk Patient smvival was asses& either to 
thedayoldcrthortoMnrctr31,1994,To~thenlatioa 
s5fw$d 
BNP 
>59pghll p 
VnrisMe (R = 32) (n f X3) Viduc 
LVEDP (mm Hg) (II = 55) 
BiOCheti 
Mn CK (IUfliter) 
0 
59 + 10 
2616 
1 
762 10 
132 z 20 
II :5 
3.3 f 0.6 
55 t 10 
(n-m) 
16 + 5 
(n=rn) 
II 
70211 
2ml 
II 
24 
25 
22 
15 
28 
7 
so + 19 
III 225 
I6 ! 6 
2.7 ,- OJi 
47 : 12 
(n=27) 
19 29 
(0 = 27) 
< om 
Ns 
< 0.41 
Ns 
NS 
CO.05 
: 001 
NS 
Ns 
Ns 
< Oaol 
< 0,ool 
c oJJot 
co.05 
Ns 
between brain natriurctii peptide and atrial natriuretic peptide 
and mortality rate, median values were used as n cutoff point 
and the Kaplan-Meier method was used to examine the 
sutvival rate in each group. The signkutcc of the ditTerence 
between sumival curves was tested by the log-rank test. The 
chi-square test was used to evaluate the ditlennccs in baseline 
characteristics between group Unpaired I tests were used to 
compare mean valuea between gmups. Linear qremion anal- 
ysis was used to assess the relation between plasma levels of 
natriuretic peptidcs and hemodynamic variables. The prognos- 
tic value of the variables was tested in a Cox ptoportional 
hazards regression analysis using the program in the PHREG 
Procedure (SASSTAT software). Predictors of survival were 
obtained by forward stepwise selection model. Data are ex- 
pressed as mean ? SD. A level of p C 0.05 was accepted as 
statistically ripiftcant. 
RS!SUltS 
The mean follow-up period was I8 monttu,(range 2 days lo 
27 months), and the follow-up rate was IWE. Eleven patients 
died dr to cardiac causes during the folk-up period, 7 
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Ta& 2. Correlation Coefficrent~ for Hemodynamic Variables and 
Plasma Natriuretk Peplide Imveh in Acute PhaP of 
Myoeardisl Infarction ---- -..X.-.-.---” ..-.....- 
KWP (‘I SV l.VEk LVI IX’ 
_._._ --____-._ _._.“__L-._ ..--... _I”.^ -.-. I.I. -s... 
On Admiatwu 
BNP 045’ II PO‘ II 44 II 42’ II,.\ I ‘ 
ANP IC1 Il.! I (1117 0 I? II 01 
Onday 
RNP II .U’ 0.42 II 47’ 
ANP 0.35’ - u.\n 
- ~~-01h~,-..--~--..--- 
l p c u.05. sv = SI~OIIC VOIUIW; other abhrcvia!wrnr il\ m ‘I3hk 1. 
patients died due to refractory heart failure, 2 patients died 
due to cardiac free-wall rupture during hospitalization, and 2 
patients died suddenly after discharge from our hospital, 
Phmn nntriumtk pe+~w revels and Benwdynamic data. 
Table 2 shows the correlation coefficients for hemodynamic 
variables and plasma natriuretic peptides fcvels on admission 
and on day 2 after onset. On admission and on day 2, plasma 
brain natriuretic peptide concentrations correlated signiti- 
cantly with the hemodynamic variahles measured at the cor- 
responding time point (pulmonary capillary wedge pressure: 
on admission, r = 0.44, on day 2, r = 0.34: cardiac index: on 
admission. r := --0.46. on day 2. r - -0.42; stroke volume: on 
admission, r = -0.44. on day 2, r = -0.47; left ventrkular 
ejection fraction: on admiuion, r = -0.42; IeE ventricular end 
diastolic pressure: on admission, r * 0.31, all p < 0.05). Plasma 
atrial natriuretic peptidc concentration, in contrast, showed a 
correlation only with pulmonary capillary wedge pressure and 
only on day 2 (r = 0.35, p < 0.05). 
Plasma oatrtontic peptfde levels and cliatcal auteome. 
Plasma brain natriuretic peptide concentrations in the patients 
who died were significantly higher than in those who survived 
at both sampling time points (on admi:,sion: I76 + 98 vs. 70 + 
58 pg/ml p rc O.(Kwl; on day 2 :25 + 7X vs. 52 C 45 pglml, p < 
O.ouO)). Plasma atrial natriuretic peptidc concentrations were 
also significantly higher in the patients who died than in those 
who survived (on admission: 170 2 54 vs. I02 ‘+ 99 pg/tnl, p < 
0.05; on day 2: I38 +_ 72 vs. I(2 +- 90 pg/ml, p < 005). The 
correlation hetwcen plasma brain uutriuretic pcptide and atrial 
natriurctic peptidc level% dt corresponding lime-points was 
weak (on admission: r z 0.30. p *:: 0.05; on day 2: r = 0.24, p c 
0.05). 
plasm aatrluretk peptide lcrels snd sunivnl cuwe. Fig 
ures 1 and 2 depict the Kaplan-Meier sunival curves. The 
patients are divided into two groups according to the median 
plasma concentrations of brain natriuretic peptidc and atrial 
natriuretic peptide. Figure I shows the results for brain natri- 
uretic peptide: the groupi with elevated plasma brain natriuretic 
peptide Ic~l on admistim ( sS’J pg/ml) and on day 2 (:>43 &ml) 
showed signiticantly higher mortality rates (p <: 0.01. p < O.(M, 
rrurclivch). Fiaure 2 .show% the results for auial natriurctic 
peptide: the group with higher plasma atrial natriurctic peptide 
Level on udmi&m (:QtO &ml) showed a signihcantly higher 
mortality mtc tp *: U.01). hut the 5uunrval ctrrve% ttn day 2 plasma 
utrul mrtrrurrtr pepude teveb did not d&r sigmficantly. 
boo 
Ptgnn 1. Kaplan-Meier analysis uf cumulative survival rate in patients 
with acute mycnlrdiul infarction cla&Ied into two groups according to 
the median value of brain nrtriuretic peptide (BNP) concernrationson 
admraion (top) and c-6 day 2 fbottom). 
To determine if plasma main natriuretic peptide level was 
assocknted with c:*n-Pac death caused by congestive heart 
failure, we examined the survival rate of all subjects excluding 
patients with sudden cardiac death (n = 2) and cardiac rupture 
(n = 2). We found that plasma brain natriuretic peptide level 
had a similar prognostic value for predicting cardiac death due 
to refractory congestive heart failure. 
Using a univariate Cox proportional hazards model, we 
found that plasma brain natriuretic pcptide concentrations oa 
Figure 2. Kaplan-Meier analysis of cumulative survival rate in Patients 
with acute mytrardial infarction classified into two groups accordingto 
the median value ofatrial natriurctic peptide (ANP) roncentrationson 
admG)o (tap) dnd on drcy 2 (bottom:. 
ANP on admiulon 
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Table 3. Univariate Relations Retween Selected Variables and 
Survival After Mpcardii lntitrction According to a Cox 
Proportional Hazards Model 
P 
Vhbk rhiaqunre VdUe 
ANPoOdmision 3.93177 0.0474 
BNP on admislion IQIIKW mlol 
ANPondby2 3.33953 O.ti7b 
BNPonday2 1544217 woo1 
Maximal CK 0.22802 O.bWJ 
Age 12.71720 O.llXkl 
Gender O.llOS4 0.7392 
HR I.14117 0354 
QCWQ a.24654 0.0091 
Cl 16.3WS5 O.CQ31 
SBP ll.63b9b 0.0031 
Qulmoaafy mnge3tion IO.54013 u.0012 
MI site 0.@7437 0.785 I 
Rcpefhuioo tltcrnpy 0.W 0.5221 
Angina patorb 1.49W 0.2209 
Hyptd 3.5tnM O&W7 
Qrovious Ml 3.31?61 O%SS 
admission and on day 2 were aj ? ’ ‘ i l ’ ; related to survival. 
Table 3 summarizes the relations between biochemical, beme 
dynamic and clinical variables and survival after my-dial 
infarction. Furthermore, according to a multivariate Cox 
proportional-hazards model, of the noninvasive variables, 
plasma brain natriuretic peptide concentration on admission 
was the signilicant and the most important noninvasive predic- 
tor of outcome (p = O.ooOl, Table 4). 
Ikdver operating ebaraw auve. We examined the 
sensitivity and specilicity of various rutoff values of plasma 
brain natriuretic peptide and attia! natriuretic peptide levels 
on admission for predicting survival. A receiver operating 
characteristic curve was constructed. The curve plotted by the 
plasma brain natriuretic peptide level on admission was a 
better predictor than the model based on the plasma atrial 
natriuretic peptide level on admission (Fig. 3). 
Several recent ieports have demonstrated that plasma atrial 
natriuretic peptide levels in the acute and subacute phases of 
Table 4. Multivariate Relations Between Selected Variables and 
Survival After Myocardii Inhrction According 10 a Chx 
Proportional Hazards Model 
Ftgure 3. Receiver opemtiag cbarscteri& auves for brala aatrh~retic 
peptide (BNP) and atrial aatriuretle peptide (ANp) predkdq ear&c 
death. The true-positive rates (sen&Gvky) and falqosltive rates (I - 
lpccimy) are ploued for various natriuletk pcptide culofl values 
prediiing cardiac death during the Iollm-up period. 
mycntardial infarction are a good predictor of survival (2937). 
However, to our knowledge, ;sur study is tbe first to report a 
relation between plasma brain natriuntic peptide level and 
prognosis after myocardial infarction. We have demonstrated 
that plasma brain natriuretic peptide matration in the 
acute and subacute phases of myocardial infarction is a pow- 
erful prediior of long-term outcome and a useful non&&e 
marker for identifying the risk of cardiac Lath. Moreover, 
plasma brain aatriuretic peptide level is more us&l as a 
predictor of survival after myocardial infa&on than plasma 
atrial natriuretic peptide level. 
Bmin- aedhasmn@amIevarIa4&In 
the present study, plasma brain natriuretic peptide conccntra- 
tions in the acute and subacute phases of myocardial i&r&on 
correlated signi6cantIy with pulmonary capillary wedge pres- 
sure, cardiac index, stroke vdume, left ventricular ejoftion 
fraction and left ventricular enddiastolic pressure. These 
findings are consistent with reports by Mukoyama and CD- 
workers that showed that pi- brain natriuretic peptide 
concentration correlated signi6cantIy with left ven+ular 
function values (25,215). Moreover, hlotwani et al. (35) dem- 
onstrated that increases in plasma brain natriuretic peptide 
levels at both early and late stages of myocardial infarction 
wcrc good indicators of alteration in left ventricular hurtion 
after treatment with angiotensin~nverting enzyme inhibitor. 
ntcr d Ita suggest that plasma brain natriuretic peptide level 
is influenced by left ventricular fun&on. 
l+vbw smdics. We have found that in the acute and 
subacute pbua of myocardial infarction, the relation between 
plasma atrial na&iuretic peptide concentration sac’ heii,&y- 
namic variables was not as strong as that of plasma brain 
natriuretic peptide. In patients with chronic he%t failure, 
plasma atrial natriwetic peptide level appears tu oe a good 
indicator of atrial oresaure or pulmowary capiIia7 .*cddaf 
pressure (cardiac fitli,y pressure) (19,2Vf$. However, in the 
acute p4ba.e of myaantial infarction *e relation beiwzen 
plasma atrial natriuretic peptide level and intracardiac pm 
u.cooI 
C~OIp6 
U.IlJ72 
U.b794 
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sure is not clear. It has been demonstrated that plasma atrial 
natriuretic pptide concentration after myocardiai infarction 
correlates significantly with cardiac index and intracardiac 
tilling pressure (37-39). Other reports have indicated that 
there is no significant relation between plasma atrial natri- 
ureticpeptide amcentration and hemodynamicvariables in the 
acute phase of myocardial infarction (40,41). The reason for 
this discrepancy is not clear, but there are several possible 
explanations. 
First, massive release of atrial natriuretic peptide from 
atrial tissue into the circulation immediately after myocardial 
infarction could lead to depletion of atrial natriuretic peptide 
stores. Thus, plasma atrial natriuretic peptide concentration 
would decrease transiently without significant hemodynamic 
changes occurring (40,42). Second, myocardial infarction rom- 
plicated by tachyarrh,thmia may cause an increase in plasma 
atrial natriuretic peptide concentration (43). Third, there are 
reports that thrombolytic therapy in the acute phase of myo- 
cardial infarction decreases plasma atrial natriuretic peptide 
concentration (41&l). Last, in the isolated perfused rat heart, 
a decrease in coronary flow reduces cardiac atrial natriuretic 
peptide release (45). These possibilities suggest that playma 
atrial natriuretic peptide level may not correlaie direct!y with 
changes in the hemodynamic values associated with left 
ventricular dysfunction in patients with acute myocardial 
infarction. 
Mechanisms of brain natriuretic peptide release. In iso- 
lated perfused rat heatis, stretching by intraventria*!ar balloon 
inflation is an independent factor to stimulate brain natriuretic 
peptide release (46). In patients with chronic heart failure 
caused by dilated cardiomyopathy, plasma brain natriuretic 
peptide concentration correlated significantly with left ventric- 
ular end-diastolic pressure (21,23). In patients with hypertro- 
phic cardiomyopathy characterized by left ventricular pressure 
overload, plasma brain natriuretic peptide lev;! increased 
more than plasma atrial natriuretic peptide level i.47). We have 
previously reported that plasma brain natriuretic peptide con- 
centration correlated signiticantly with left ventricular end- 
diastolic pressure but not with left atrial pressure in patients 
with mitral stenosis (34). These findings indicate that, after 
myocardial infarction, the increase in venticular wali stress/ 
tension may be an important fac:nr in stimulating brain 
natriuretic peptide synthesis and reiease from ventricular 
cardiomyocytes. 
Two additional mechanisms may %nulate brain nlltriuretic 
peptide release in patients with acute myocardial infarction: 1) 
it has been shown that hypoxia is an independent stimulus for 
brain natriuretic peptide release (48). suggesting that myocar- 
dial &hernia stimulates the release of brain natriuretic pep- 
tide; 2) because the increase in plasma brain natriuretic 
peptide concentration after myocardial infarction is closely 
related to infarct size (33). brain natriuretic peptide. like 
cardiac enzymes or macromolecuies. may De refeased from tie 
infarcted or horder area behvren the infarcted and nonin- 
far&d areas. The observation that brain natriurettc peptide 
mRNA is expressed in ventricular tissue more rapidly than 
atrial natriuretic peptide mRNA in the rat niyocardial infarc- 
tion model (49) suggests that brain natriuretic peptide produc- 
tion may be. immediately increased by the changes in ventric- 
ular function that occur after myocardial damage cr 
myocardial &hernia. Thus, after myocardial infarction. cardiac 
production and release of brain natriuretic peptide may be 
immediately accelerated, in contrast to atrial natriuretic pep- 
tide, and plasma brain nat+.retic peptide level may indicate 
the severity of left ventricular dysfunction and myocardial 
damage. 
Study limitations. Various coronary interventions were 
used in the acute stage of myocardial infarction in this study. 
These ditTerences in treatment may have affected prognosis. 
However, there ~VB no difference in coronary interventions 
between the two groups classified by plasma brain natriuretic 
peptide level on admission (Table 1). No sign&ant differences 
in the subsequent survival rate were found among the varia- 
tions of coronary interventions in the acute phase of myocar- 
dial infarction in the present study group. Moreover, presence 
of angina pectcris before onset, history of previous myocardial 
infarction and difference in infaction site did not at&t 
survival rate in the small number of our subjects. The effect of 
drug treatment (that is, angiotensin-converting enzyme inhi 
itor$ beta-receptor blockers) after myocardial infarction was 
not assessed in the prtisent study. However, because. few 
patients were given ulgiotensiu-converting enzyme inhibitors 
(n = 5) or beta-blockers (n = II), there was no Merence 
between the two groups. These medications, therefore, may 
not have significantly biased the results of the present study. 
Conelusions. In this study, we found that plasma brain 
natriuretic peptide level reflects left ventricular function more 
directly than plasma atrial natriuretic peptide level does. 
Increased plasma brain natriuretic peptide concentration was 
significantly related to mortality. We suggest that measure- 
ment of plasma brain natriuretic peptide level in the early 
phase of myocardial infarctioil may be a useful noninvasive 
method for identifying individuals at high risk of cardiac death 
after myocardial infaction. 
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